Morgan Stanley’s Keryx Biopharmaceuticals Inc KERX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-418,255
| Closed | -$1.42M | – | 6892 |
|
|
2018
Q3 | $1.42M | Sell |
418,255
-746,166
| -64% | -$2.69M | ﹤0.01% | 4267 |
|
|
2018
Q2 | $4.38M | Buy |
1,164,421
+771,315
| +196% | +$3.76M | ﹤0.01% | 3301 |
|
|
2018
Q1 | $1.61M | Buy |
393,106
+27,958
| +8% | +$130K | ﹤0.01% | 4196 |
|
|
2017
Q4 | $1.7M | Sell |
365,148
-81,586
| -18% | -$450K | ﹤0.01% | 4169 |
|
|
2017
Q3 | $3.17M | Buy |
446,734
+80,735
| +22% | +$581K | ﹤0.01% | 3431 |
|
|
2017
Q2 | $2.65M | Sell |
365,999
-65,182
| -15% | -$407K | ﹤0.01% | 3535 |
|
|
2017
Q1 | $2.66M | Sell |
431,181
-25,919
| -6% | -$142K | ﹤0.01% | 3548 |
|
|
2016
Q4 | $2.68M | Buy |
457,100
+302,403
| +195% | +$1.65M | ﹤0.01% | 3653 |
|
|
2016
Q3 | $821K | Sell |
154,697
-83,233
| -35% | -$449K | ﹤0.01% | 4176 |
|
|
2016
Q2 | $1.57M | Buy |
237,930
+120,261
| +102% | +$672K | ﹤0.01% | 3619 |
|
|
2016
Q1 | $550K | Sell |
117,669
-51,586
| -30% | -$206K | ﹤0.01% | 4378 |
|
|
2015
Q4 | $854K | Buy |
169,255
+16,976
| +11% | +$80.7K | ﹤0.01% | 4178 |
|
|
2015
Q3 | $536K | Sell |
152,279
-39,836
| -21% | -$267K | ﹤0.01% | 4562 |
|
|
2015
Q2 | $1.92M | Buy |
192,115
+5,100
| +3% | +$54.7K | ﹤0.01% | 3672 |
|
|
2015
Q1 | $2.38M | Sell |
187,015
-85,670
| -31% | -$1.1M | ﹤0.01% | 3437 |
|
|
2014
Q4 | $3.86M | Sell |
272,685
-165,912
| -38% | -$2.57M | ﹤0.01% | 2970 |
|
|
2014
Q3 | $6.03M | Buy |
438,597
+212,737
| +94% | +$3.26M | ﹤0.01% | 2472 |
|
|
2014
Q2 | $3.47M | Buy |
225,860
+45,333
| +25% | +$643K | ﹤0.01% | 3014 |
|
|
2014
Q1 | $3.08M | Buy |
180,527
+48,198
| +36% | +$727K | ﹤0.01% | 3054 |
|
|
2013
Q4 | $1.71M | Buy |
132,329
+6,973
| +6% | +$83.3K | ﹤0.01% | 3493 |
|
|
2013
Q3 | $1.26M | Sell |
125,356
-10,421
| -8% | -$92.7K | ﹤0.01% | 3594 |
|
|
2013
Q2 | $1.01M | Buy |
+135,777
| New | +$1.06M | ﹤0.01% | 3718 |
|
Morgan Stanley's KERX Position: Q4 2018 in Review
Morgan Stanley sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2018, closing a stake of 418,255 shares — an estimated $1.42M sold.
Morgan Stanley first reported a position in KERX in Q2 2013 and held it in 22 quarters. The position peaked at $6.03M in Q3 2014. 1 fund tracked by Wall St. Rank holds KERX as of Q4 2018.
- Morgan Stanley reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
- Morgan Stanley sold 418,255 Keryx Biopharmaceuticals Inc shares in Q4 2018, an estimated $1.42M.
- Morgan Stanley first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 22 quarters.
- Morgan Stanley's Keryx Biopharmaceuticals Inc position peaked at $6.03M in Q3 2014.
- 1 fund tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2018.
Based on Morgan Stanley's 13F filing for Q4 2018, filed 14 Feb 2019.